{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T21:33:35Z","timestamp":1773869615203,"version":"3.50.1"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012399","name":"BARDA","doi-asserted-by":"publisher","award":["HHSO100201300011C"],"award-info":[{"award-number":["HHSO100201300011C"]}],"id":[{"id":"10.13039\/100012399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100021704","name":"Administration for Strategic Preparedness and Response","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100021704","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contemporary Clinical Trials Communications"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.conctc.2025.101572","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T12:44:56Z","timestamp":1763642696000},"page":"101572","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Impact of updated regulatory guidelines on study results in contemporary uncomplicated urinary tract infection clinical trials and implications for trial conduct and drug development: a comparative analysis with EAGLE-2 and EAGLE-3"],"prefix":"10.1016","volume":"48","author":[{"given":"Florian","family":"Wagenlehner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith S.","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7048-8086","authenticated-orcid":false,"given":"David A.","family":"Talan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3115-5016","authenticated-orcid":false,"given":"Amanda J.","family":"Sheets","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole E.","family":"Scangarella-Oman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Jarvis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0063-0614","authenticated-orcid":false,"given":"Jeremy","family":"Dennison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salim","family":"Janmohamed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Helgeson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Perry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.conctc.2025.101572_bib1","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1001\/jama.2018.3627","article-title":"Effect of 5-day nitrofurantoin vs single-dose fosfomycin on clinical resolution of uncomplicated lower urinary tract infection in women: a randomized clinical trial","volume":"319","author":"Huttner","year":"2018","journal-title":"JAMA"},{"issue":"20","key":"10.1016\/j.conctc.2025.101572_bib2","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1001\/archinte.167.20.2207","article-title":"Short-course nitrofurantoin for the treatment of acute uncomplicated cystitis in women","volume":"167","author":"Gupta","year":"2007","journal-title":"Arch. Intern. Med."},{"issue":"482","key":"10.1016\/j.conctc.2025.101572_bib3","first-page":"729","article-title":"Randomised controlled trial of nitrofurantoin versus placebo in the treatment of uncomplicated urinary tract infection in adult women","volume":"52","author":"Christiaens","year":"2002","journal-title":"Br. J. Gen. Pract."},{"issue":"11","key":"10.1016\/j.conctc.2025.101572_bib4","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1016\/S0149-2918(00)86734-X","article-title":"Comparison of single-dose fosfomycin and a 7-day course of nitrofurantoin in female patients with uncomplicated urinary tract infection","volume":"21","author":"Stein","year":"1999","journal-title":"Clin. Ther."},{"key":"10.1016\/j.conctc.2025.101572_bib5","article-title":"Uncomplicated urinary tract infections: developing drugs for treatment","year":"2019","journal-title":"Guidance Industry"},{"key":"10.1016\/j.conctc.2025.101572_bib6","unstructured":"European Medicines Agency (EMA), Evaluation of medicinal products indicated for treatment of bacterial infections \u2013 scientific guideline (2022) Available from: https:\/\/www.ema.europa.eu\/en\/evaluation-medicinal-products-indicated-treatment-bacterial-infections-scientific-guideline."},{"issue":"4","key":"10.1016\/j.conctc.2025.101572_bib8","first-page":"570","article-title":"Mechanistic and structural basis for the actions of the antibacterial gepotidacin against ACS","volume":"5","author":"Gibson","year":"2019","journal-title":"Infect. Dis."},{"issue":"7309","key":"10.1016\/j.conctc.2025.101572_bib9","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1038\/nature09197","article-title":"Type IIA topoisomerase inhibition by a new class of antibacterial agents","volume":"466","author":"Bax","year":"2010","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.conctc.2025.101572_bib10","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1021\/acsinfecdis.3c00346","article-title":"Interactions between gepotidacin and Escherichia coli gyrase and topoisomerase IV: genetic and biochemical evidence for well-balanced dual-targeting","volume":"10","author":"Oviatt","year":"2024","journal-title":"ACS Infect. Dis."},{"issue":"4","key":"10.1016\/j.conctc.2025.101572_bib11","article-title":"Antimicrobial activity of gepotidacin tested against Escherichia coli and Staphylococcus saprophyticus isolates causing urinary tract infections in medical centers worldwide (2019 to 2020)","volume":"67","author":"Ryan Arends","year":"2023","journal-title":"Antimicrob. Agents. Chemother."},{"issue":"10428","key":"10.1016\/j.conctc.2025.101572_bib12","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0140-6736(23)02196-7","article-title":"Oral gepotidacin versus nitrofurantoin in patients with uncomplicated urinary tract infection (EAGLE-2 and EAGLE-3): two randomised, controlled, double-blind, double-dummy, phase 3, non-inferiority trials","volume":"403","author":"Wagenlehner","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.conctc.2025.101572_bib13","unstructured":"Medicinces and Healthcare products Regulatory Agency (MHRA), Fluoroquinolone antibiotics: must now only be prescribed when other commonly recommended antibiotics are inappropriate (2025) Available from: https:\/\/www.gov.uk\/drug-safety-update\/fluoroquinolone-antibiotics-must-now-only-be-prescribed-when-other-commonly-recommended-antibiotics-are-inappropriate#advice-for-healthcare-professionals."},{"key":"10.1016\/j.conctc.2025.101572_bib14","unstructured":"GSK, Blujepa (gepotidacin) approved by US FDA for treatment of uncomplicated urinary tract infections (uUTIs) in female adults and paediatric patients 12 years of age and older (2025) Available from:https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/blujepa-gepotidacin-approved-by-us-fda-for-treatment-of-uncomplicated-urinary-tract-infections\/."},{"issue":"5","key":"10.1016\/j.conctc.2025.101572_bib16","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11908-016-0522-0","article-title":"Urine culture in uncomplicated UTI: interpretation and significance","volume":"18","author":"Stapleton","year":"2016","journal-title":"Curr. Infect. Dis. Rep."},{"issue":"11","key":"10.1016\/j.conctc.2025.101572_bib17","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofad557","article-title":"Impact of the 2019 food and drug administration guidance for uncomplicated urinary tract infection on treatment response rates: a reanalysis of a clinical trial of nitrofurantoin vs fosfomycin","volume":"10","author":"Grant","year":"2023","journal-title":"Open. Forum. Infect. Dis."},{"issue":"6","key":"10.1016\/j.conctc.2025.101572_bib18","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1007\/s40121-022-00706-9","article-title":"Design of two phase III, randomized, multicenter studies comparing gepotidacin with nitrofurantoin for the treatment of uncomplicated urinary tract infection in female participants","volume":"11","author":"Perry","year":"2022","journal-title":"Infect. Dis. Ther."},{"key":"10.1016\/j.conctc.2025.101572_bib19","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jgar.2020.01.027","article-title":"Systematic review and meta-analysis to estimate the antibacterial treatment effect of nitrofurantoin for a non-inferiority trial in uncomplicated urinary tract infection","volume":"22","author":"Mitrani-Gold","year":"2020","journal-title":"J. Glob. Antimicrob. Resist."},{"issue":"10","key":"10.1016\/j.conctc.2025.101572_bib20","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1093\/cid\/ciad010","article-title":"Discordant clinical and microbiological outcomes are associated with late clinical relapse in clinical trials for complicated urinary tract infections","volume":"76","author":"Kadry","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.conctc.2025.101572_bib21","article-title":"Symptomatic treatment of uncomplicated lower urinary tract infections in the ambulatory setting: randomised, double blind trial","volume":"359","author":"Kronenberg","year":"2017","journal-title":"BMJ Open"},{"issue":"6","key":"10.1016\/j.conctc.2025.101572_bib22","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1007\/s11136-023-03348-7","article-title":"Development and psychometric validation of a patient-reported outcome measure of recurrent urinary tract infection impact: the recurrent UTI impact questionnaire","volume":"32","author":"Newlands","year":"2023","journal-title":"Qual. Life Res."},{"issue":"8","key":"10.1016\/j.conctc.2025.101572_bib23","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1007\/s00345-019-02948-8","article-title":"Additional assessment of acute cystitis symptom score questionnaire for patient-reported outcome measure in female patients with acute uncomplicated cystitis: part II","volume":"38","author":"Alidjanov","year":"2020","journal-title":"World. J. Urol."},{"key":"10.1016\/j.conctc.2025.101572_bib24","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"Br. Med. J."},{"issue":"Suppl A","key":"10.1016\/j.conctc.2025.101572_bib25","first-page":"67","article-title":"A trial comparing low-dose, short-course ciprofloxacin and standard 7 day therapy with co-trimoxazole or nitrofurantoin in the treatment of uncomplicated urinary tract infection","volume":"43","author":"Iravani","year":"1999","journal-title":"J. Antimicrob. Chemother."},{"issue":"1","key":"10.1016\/j.conctc.2025.101572_bib26","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1001\/jama.1995.03520250057034","article-title":"Randomized comparative trial and cost analysis of 3-day antimicrobial regimens for treatment of acute cystitis in women","volume":"273","author":"Hooton","year":"1995","journal-title":"JAMA"},{"issue":"Suppl A","key":"10.1016\/j.conctc.2025.101572_bib27","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1093\/jac\/33.suppl_A.121","article-title":"Nitrofurantoin modified release versus trimethoprim or co-trimoxazole in the treatment of uncomplicated urinary tract infection in general practice","volume":"33","author":"Spencer","year":"1994","journal-title":"J. Antimicrob. Chemother."},{"issue":"6","key":"10.1016\/j.conctc.2025.101572_bib28","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/BF01871127","article-title":"Fosfomycin trometamol in a single dose versus seven days nitrofurantoin in the treatment of acute uncomplicated urinary tract infections in women","volume":"15","author":"Van Pienbroek","year":"1993","journal-title":"Pharm. World Sci."},{"issue":"7","key":"10.1016\/j.conctc.2025.101572_bib29","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1742-1241.1988.tb08585.x","article-title":"Comparison of Mictral with amoxycillin, trimethoprim and nitrofurantoin in the treatment of acute cystitis","volume":"42","author":"Lightstone","year":"1988","journal-title":"Br. J. Clin. Pract."},{"issue":"10","key":"10.1016\/j.conctc.2025.101572_bib30","first-page":"663","article-title":"A comparative study of pipemidic acid and nitrofurantoin in the treatment of uncomplicated urinary tract infections","volume":"72","author":"Meyer","year":"1987","journal-title":"S. Afr. Med. J."}],"container-title":["Contemporary Clinical Trials Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451865425001462?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451865425001462?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T14:13:11Z","timestamp":1773843191000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2451865425001462"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":28,"alternative-id":["S2451865425001462"],"URL":"https:\/\/doi.org\/10.1016\/j.conctc.2025.101572","relation":{},"ISSN":["2451-8654"],"issn-type":[{"value":"2451-8654","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of updated regulatory guidelines on study results in contemporary uncomplicated urinary tract infection clinical trials and implications for trial conduct and drug development: a comparative analysis with EAGLE-2 and EAGLE-3","name":"articletitle","label":"Article Title"},{"value":"Contemporary Clinical Trials Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.conctc.2025.101572","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 GSK. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101572"}}